Table 1. Clinical characteristics of patients with familial and sporadic sarcoidosis.
| Characteristics | Familial N=68 |
Sporadic N=1062 |
P value |
|---|---|---|---|
| Age (y) at diagnosis | 48.8±13.9 | 51.3±13.8 | 0.100 |
| Sex (male) | 28 (41.2) | 482 (45.4) | 0.499 |
| BMI at diagnosis, median (IQR)* | 26.8 (23.9–31.0) | 27.7 (24.6–31.1) | 0.250 |
| Smoking† | |||
| No smoking | 47 (69.1) | 650 (64.2) | 0.409 |
| History of smoking | 12 (17.6) | 219 (21.6) | 0.439 |
| Active smoking | 9 (13.2) | 144 (14.2) | 0.822 |
| Follow-up -time (y), median (IQR)‡ | 3.5 (2.0–8.5) | 2.9 (1.7–6.0) | 0.020 |
| Follow-up <2 y | 18 (26.5) | 336 (31.6) | 0.373 |
| Follow-up 2–5 y | 26 (38.2) | 401 (37.8) | 0.937 |
| Follow-up >5 y | 24 (35.3) | 324 (30.5) | 0.407 |
| Follow-up -time (treatment completed) (y), median (IQR)§ | 3.4 (1.8–7.4) | 2.6 (1.5–5.2) | 0.041 |
| Manifestation | |||
| Lungs and lymph nodes | 44 (64.7) | 630 (59.3) | 0.380 |
| Lymph nodes | 18 (26.5) | 248 (23.4) | 0.557 |
| Eyes | 14 (20.6) | 99 (9.3) | 0.003 |
| Skin | 11 (16.2) | 202 (19.0) | 0.561 |
| Kidneys | 8 (11.8) | 54 (5.1) | 0.019 |
| Lungs | 4 (5.9) | 69 (6.5) | 1.000 |
| Liver | 4 (5.9) | 30 (2.8) | 0.143 |
| Spleen | 4 (5.9) | 69 (6.5) | 1.000 |
| Heart | 3 (4.4) | 95 (8.9) | 0.266 |
| Joints | 5 (7.4) | 90 (8.5) | 0.747 |
| Bones | 2 (2.9) | 13 (1.2) | 0.227 |
| Organ involvement (No.) | |||
| 1 | 15 (22.1) | 235 (22.1) | 0.989 |
| ≥ 2 | 53 (77.9) | 827 (77.9) | 0.989 |
| ≥ 3 | 29 (42.6) | 311 (29.3) | 0.020 |
| On medication for sarcoidosis | 40 (58.8) | 525 (49.4) | 0.133 |
| Medication for pulmonary sarcoidosis | 25 (36.8) | 308 (29.0) | 0.173 |
| Medication for extra-pulmonary sarcoidosis | 23 (33.8) | 285 (26.8) | 0.210 |
| Sarcoidosis medication | |||
| Oral corticosteroid | 38 (55.9) | 472 (44.4) | 0.057 |
| Inhaled corticosteroid | 8 (11.8) | 82 (7.7) | 0.233 |
| Methotrexate | 5 (7.4) | 52 (4.9) | 0.383 |
| Azathioprine | 3 (4.4) | 19 (1.8) | 0.142 |
| Infliximab | 1 (1.5) | 11 (1.0) | 0.527 |
| Other | 0 | 39 (3.7) | 0.165 |
| Time on medication (m), median (IQR)¶ | 20.8 (9.9–45.3) | 17.1 (9.3–32.1) | 0.478 |
The data are presented as the number (%) or mean±SD unless otherwise indicated.
*
Data from 51 patients with familial sarcoidosis and 688 patients with sporadic sarcoidosis.
†
Data from 68 patients with familial sarcoidosis and 1013 patients with sporadic sarcoidosis.
‡
Data from 68 patients with familial sarcoidosis and 1061 patients with sporadic sarcoidosis. Includes patients whose treatment continues in specialised care.
§
Data from 55 patients with familial sarcoidosis and 836 patients with sporadic sarcoidosis. Includes patients whose treatment in secondary care has been completed.
¶
Data from 23 patients with familial sarcoidosis and 237 patients with sporadic sarcoidosis.
BMI, body mass index; y, years.